BriaCell Therapeutics (BCTX)
2.68
-0.20 (6.94%)
Upcoming Events
Latest Headlines
Form 10-Q BriaCell Therapeutics For: Apr 30
June 9, 2026 4:06 PM - SEC Filing
Form 8-K BriaCell Therapeutics For: May 31
June 3, 2026 6:04 AM - SEC Filing
Form 424B5 BriaCell Therapeutics
June 2, 2026 8:01 AM - SEC Filing
BriaCell Therapeutics Announces Pricing of Offering
May 31, 2026 7:59 PM - Globe NewsWire
BriaCell develops ovarian cancer immunotherapy candidate
May 15, 2026 7:31 AM - StreetInsider
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
May 15, 2026 7:30 AM - Globe NewsWire
BriaCell completes manufacturing of prostate cancer therapy supplies
May 14, 2026 7:31 AM - StreetInsider
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
May 14, 2026 7:30 AM - Globe NewsWire
BriaCell adds Penn Medicine cancer center to phase 3 breast cancer trial
May 13, 2026 7:30 AM - StreetInsider
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
May 13, 2026 7:30 AM - Globe NewsWire
BriaCell enrolls over 230 patients in phase 3 breast cancer study
May 12, 2026 7:30 AM - StreetInsider
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
May 12, 2026 7:30 AM - Globe NewsWire
BriaCell adds NYU cancer center to phase 3 breast cancer trial
May 7, 2026 7:30 AM - StreetInsider
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
May 7, 2026 7:30 AM - Globe NewsWire
BriaCell receives FDA clearance for breast cancer immunotherapy trial
May 6, 2026 7:31 AM - StreetInsider
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
May 6, 2026 7:30 AM - Globe NewsWire
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
April 27, 2026 7:30 AM - Globe NewsWire
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
April 21, 2026 7:30 AM - Globe NewsWire
BriaCell presents cancer therapy data at 2026 AACR meeting
April 20, 2026 7:31 AM - StreetInsider
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
April 20, 2026 7:30 AM - Globe NewsWire
Form 8-K BriaCell Therapeutics For: Mar 31
March 31, 2026 4:11 PM - SEC Filing
BriaCell subsidiary BriaPro completes sCD80 license acquisition
March 31, 2026 4:06 PM - StreetInsider
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
March 31, 2026 4:05 PM - Globe NewsWire
Full Article List